GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » Net Margin %

INNMF (Amplia Therapeutics) Net Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Amplia Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Amplia Therapeutics's Net Income for the six months ended in Sep. 2024 was $-1.91 Mil. Amplia Therapeutics's Revenue for the six months ended in Sep. 2024 was $0.00 Mil. Therefore, Amplia Therapeutics's net margin for the quarter that ended in Sep. 2024 was 0.00%.

The historical rank and industry rank for Amplia Therapeutics's Net Margin % or its related term are showing as below:


INNMF's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -122.29
* Ranked among companies with meaningful Net Margin % only.

Amplia Therapeutics Net Margin % Historical Data

The historical data trend for Amplia Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Net Margin % Chart

Amplia Therapeutics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Amplia Therapeutics Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Amplia Therapeutics's Net Margin %

For the Biotechnology subindustry, Amplia Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amplia Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Net Margin % falls into.


;
;

Amplia Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Amplia Therapeutics's Net Margin for the fiscal year that ended in Mar. 2024 is calculated as

Net Margin=Net Income (A: Mar. 2024 )/Revenue (A: Mar. 2024 )
=-2.953/0
= %

Amplia Therapeutics's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin=Net Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-1.905/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amplia Therapeutics  (OTCPK:INNMF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Amplia Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Amplia Therapeutics Business Description

Traded in Other Exchanges
Address
350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.